drugset / Trial / NCT00804973

Study in Participants With Acute Migraines Headaches

NCT00804973

Phase 2 Terminated 120 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.

Timeline

Start
2008-11
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2590443 Unknown 200 mg Oral
Comparator Sumatriptan Unknown 6 mg Other

Indications